

## **Comparative investigation of spot kit versus RTPCR in COVID active patients**

### **ABSTRACT:**

On 31 December 2019, numerous pneumonitis occurrences of pneumonitis of uncertain origin, in Wuhan city, People's Republic of China. The previously unknown origin was identified and designated the 2019 new Coronavirus in January 2020. WHO eventually dubbed it Coronavirus disease 2019 (COVID-19). The infection has been identified as Coronavirus-2, which causes severe acute respiratory illness (SARS-CoV-2). It was crucial to control the rapid evolving SARS-CoV-2-associated **Coronavirus disease 2019 pandemic**. In order to do so, highly sensitive and specific lab diagnostic **assessments like RTPCR and Genome sequencing helped** in identifying the cases at an early stage which further helped increasing the rate of survival. With time multiple tests were formulated which aided us but a need for the best and more accurate one was still needed. Some of these tests were quick but had a lower level efficacy while the old tests were accurate but are really slow. In this review article, we have formulated a comparative investigation of spot kit versus RTPCR in **COVID** active Patients from case reports, original investigation articles published by PubMed and Google scholar. With the **help of these articles** we have come a the best possible conclusion. **The conclusion came out as COVID-19 patients found positive by RTPCR but negative by spot kit are uncommon to be infectious.**

**KEYWORDS:** COVID-19 , SARS-CoV-2, lab diagnostic assessments , RTPCR, Spot kit

### **INTRODUCTION**

Multiple occurrences of pneumonitis with an uncertain origin have been observed in the city of Wuhan, People's Republic of China, since **December 2019**. A formerly uncertain -cyclotron virus was discovered using unbiased sequencing **sequencing of patient samples**. A novel Coronavirus has been discovered in human airway epithelial cells. SARS CoV2, which origins Coronavirus Disease, was

discovered in cells and named SARS CoV2 (COVID)-19. COVID-19, like MERS-CoV and SARS-CoV, is a member of the Coronavirus family that infects humans.(1) Previous research has revealed that the great majority of COVID-19 Patients had been exposed to the Wuhan epidemic area. Fever and cough were among the symptoms in institutionalized Patients. Imaging is crucial in the diagnosis and evaluation of disease.(1-8) In recent months, the COVID-19 breakout has had a significant impact on in medical institution settings. This opinion discusses current concerns and challenges in the lab detection of the Coronavirus 2 that causes severe acute respiratory syndrome (SARS-CoV-2). Reverse transcription-quantitative PCR (RT q PCR) utilizing nasopharyngeal (N) swabs, throat (T) swabs, or saliva is the gold standard for COVID-19 diagnosis As there are studies mentioning about APOL1 gene as a “high-risk gene”, patients presenting with collapsing glomerulonephritis should be tested for the inheritance of the gene , if the patient is an African descendent. More comparative studies and researches based on evidences must to done to expand the knowledge about the mechanisms of renal damage, development of AKI and role of APOL1 gene. Journals on renal involvement in SARS-CoV-2 infected children are very few until now, which should be considered an important topic to be researched on ,as it would be of great help in future incidences . Since December, a paramount of research has been done to find ways to bring down the morbidity and mortality associated with this viral infection. The wait for a vaccine forces the world to find alternative methods to decrease this morbidity. Research has proven that if renal damage can be prevented or managed at the right time, it can prove to save lives and reduce deaths caused by this vicious virus. (2-8) However, the RTPCR assessment is not fast (it typically takes 3 to 4 hours for conclusion to arrive), and it needs specialized lab equipment and skilled technicians, while antigen assessments are simple and could be assessment routinely in in hospital setting labs. We present you a comparative investigation b/w Rapid Antigen Test (RAT) and RTPCR technique.

### **Contrast between RTqPCR and the antigen assessment**

#### **INVESTIGATION 1**

##### **Patients and samples**

The Institutional Review Board of the Yamanashi Central Medical Institution’s Genome Research Committee authorized a study in which 323 nasopharyngeal swabs were collected from individuals at Yamanashi Central Medical institution. Cotton swabs and viral transport medium were used to capture all samples in UTM1 (Copan Diagnostics, Murrieta, CA, USA). Until nucleic acid extraction, the viral transport medium were kept at 4<sup>0</sup>C. Within 2 hours of collecting swabs, total nucleic acids were extracted.




Fig. 1.

### Investigation 1 Outcome:

RTqPCR was used to determine the antigen assessment on 313 nasopharyngeal swabs, with 58 positive samples from 11 infected Patients and 255 negative samples from 215 non-infected persons. The antigen assessment was performed on these samples in a blinded manner.

The PCR-positive samples had a median antigen level of 1.56 pg/mL (range 0.02–094,095 pg/mL), while the PCR-negative samples had a median antigen level of 0.27 pg/mL (range 0–2.3 pg/mL) (Fig. 1A). The PCR-positive samples had a substantially higher mean antigen level than the PCR-negative samples ( $p = 0.32$ , Student's t- assessment, Fig. 1A).

Receiver operating characteristic (ROC) curve analysis were used to estimate the cutoff antigen level for determining SARS-CoV-2 infection status. The accuracy achieved its pinnacle when the antigen level limit was set to 1.31 pg/mL. The antigen assessment has an AUC value of 0.868 +0.034, indicating that it accurately recognized SARS-CoV-2, according to ROC studies (Fig. 1B).

True-positive, false-positive, true-negative, and false-negative findings were 32, 1, 254, and 26 correspondingly (Fig. 1C). The antigen assessment detected SARS-CoV-2 infection status with a sensitivity of 55.2 percentage and a specificity of 99.6 percentage when the RTqPCR findings were utilized as a reference. The antigen assessment and RTqPCR had a 91.4 percentage (286/313) overall concordance.

### INVESTIGATION 2


RTPCR was used to evaluate various types of tissues from 235 individuals with confirmed COVID-19 in a investigation by Wang et al. Only 156 (22%) of 398 pharyngeal swabs were found

to be positive. They only took eight nasal swabs, and five (64%) of them were positive. Wang et colleagues also looked at broncho alveolar lavage (BAAL) fluid and sputum samples, which were found to be positive in 93 percentage and 72 percentage of Patients, respectively.(9)(10)

### INVESTIGATION 3

#### Patients

Between September 2nd and October 7th, 2020, 412 Patients with in medical institution setting suspicion of COVID-19 (median antigen 41 years, range 11 years, 68 percentage female) were enrolled in this prospective investigation, with 427 adults (median antigen 26 years, range 19 to 21 years) and 85 children (16 years old, median 11 years, range 1 to 16 years) attending primary care centres of the Clinico-Malvarrosa Health Department in Malvarrosa (Spain). Only Patients who had similar indications or symptoms in the previous week were included in the investigation. The INCLIVA Research Ethics Committee of the Medical institution Clinico-de-Valencia (HCU) gave its approval to the project.



**Fig. 2. Study investigation**

The various variant forms which were testified in India have caused a great , enormous expansion in the amount of registered cases. Evolving alternates not only caused panic among public , increment in transmissibility, death rate and unwholesomeness , but also have the capacity to conceal identification by preceding indicative assessments, which can possibly Interrupt the demonstration, analysis and cure, possess the ability to cause superimposed on infection of same type in previously infected and recovered healthy individuals, and immunized individual gets the disease they are vaccinated against

#### SARS COV-2 assessment

In a study conducted in 2020 by the Turkish society of nephrology, it was mentioned that among the 578 COVID-19 patients on whom the study was conducted, 13.3-35.7% patients were in need of kidney replacement therapy(KRT). 70.5% of the 578 patients had hypertension, 43.8% had

diabetes mellitus and 37.6% had chronic kidney disease as comorbidities. The Reactive airway disease (RAD) evaluation was performed immediately following sample collection, as per the manufacturer's instructions (reading at 15 min). There are seven recognized coronaviruses that are known to cause human infections, most of them belong to Betacoronavirus except the first two (229E and NL63) which belong to Alphacoronavirus. This virus comprises of a nucleocapsid, surrounded by an envelope. It measures 120 nm in size; has a helical symmetry. It possesses 4 structural proteins and 16 nonstructural proteins and several other accessory proteins. Nucleobases consists of a positive-sense The envelope is lipoprotein in nature; the lipid part is host-derived into which a number of proteins are embedded such as: Spike protein (S): Helps in the attachment to the host cells. Neutralizing antibodies are produced against S protein are protective in nature. (11)(12)

### **SARS CoV-2 culture**

Before being processed for culture in Vero E6 cells, samples obtained in UTM were kept at e80 C for up to 2 weeks. RTPCR confirmed the presence of SARS COV-2.

### **Analyses statistical**

The antigen agreement between the RAD assessment and RTPCR was investigated using Cohen's k statistics. To compare median differences, the Mann-Whitney U-test was utilized. Using receiver operating characteristic (ROC) curves, the SARS CoV-2 RTPCR cycle threshold (CT) and RNA loads that best differentiate b/w RTPCR/RAD and RADe samples were identified. On both sides, P values of less than 0.05 were considered significant. For statistical analysis, SPSS version 25.0 was utilized (SPSS, Chicantigeno, IL, USA).(13)

### **INVESTIGATION 3 OUTCOME-**

Out of 412 Patients, 43 (10.4%) assessment positive by RTPCR and RAD, while 358 (86.9%) assessment negative by both methods, with 11 individuals having discordant outcomes (RTPCR/RAD) (2.7 percentage ). The two methods were in good antigen agreement (k 0.87, 95 percentage CI 0.79e0.94). RAD's overall specificity and sensitivity were both 100% (95 percentage confidence interval: 98.7e100%) and 79.6% (95 percentage confidence interval: 67.0e88.8%), respectively. Patients with 5-day in medical institution setting regimens had (14) slightly higher sensitivity (80.4 percentage, 95 percentage CI 66.8e89.3 percentage) (Fig. 2A).

Adults had higher sensitivity (82.6 percentage, 95 percentage confidence interval 69.3e90.9 percentage) than children (62.5 percentage , 95 percentage CI 30.6e86.3 percentage).(14)

For an estimated prevalence of 5% and 10% (the incidence of COVID-19 in our Health Department throughout the investigation period was within that range), the overall RAD negative predictive value was 99 percentage (95 percentage CI 97.4e99.6) and 97.9% (95 percentage CI 95.9 98.9), respectively (the incidence of COVID-19 in our Health Department during the investigation period was within that range).

In RTPCR/RAD samples, CT values were substantially higher and SARS COV-2 RNA burdens were significantly lower (p 0.001) than in R T - P C R/RAD samples (Fig. 2B,C). With a sensitivity and specificity of 100 percentage, ROC curve analysis revealed that the R T - P C RCT 25 and S A R S - C o V - 2RNA loads >5.9 log<sub>10</sub> copies/mL criteria best differentiated b/w R T - P C



limited amount, producing no sickness but eliciting immune responses comparable to those elicited by natural infection.

The results of case study demonstrate that IgM is the first antibody to rise in individuals after vaccination as it is the first line of defense, however IgG titers are the maximum in number especially in age groups of 18-36, then as age advances the number of the titer decreases with almost negligible response in adults > 76 years of age. COVID-19's current, unprecedented worldwide outbreak has underlined the need of lab identification of human Coronavirus contamination in order to prevent the spread and properly treat patients who have a significant infection. This topic has addressed current difficulties regarding SARS-CoV-2 assessment. For early diagnosis or screening, an NP swab is preferred over an OP swab because it delivers better diagnostic results, is more patient-friendly, and is safer for the operator. To boost sensitivity, an NP swab may be combined with an OP swab, but this would need twice as many swabs. Consequences such as: Tissue damage and necrosis Further recruitment of leukocytes Impaired gas exchange, which leads to reduced Blood oxygenation and tissue hypoxia. Endothelial damage of pulmonary vasculature, Leading to vasodilation, microvascular thrombosis and hemorrhage and hypercoagulability Allows passage of fluids from the blood vessels to lungs which leads to pulmonary edema. These infiltrates in lungs appears as ground glass appearance in chest imaging. Cytokines can also induce damage to organs of body such as heart kidney, heart, liver, most of the vital organs. There occur several events such as sepsis, shock, and multiorgan failure, kidney damage and cardiac injury. In patients with severe disease, if the initial screening test is negative, the need for further testing or bronchoscopy must be noted. The ultimate outcome was RT-PCR R-proven. Patients with COVID-19 who use a spot kit and test negative for negative are unlikely to be infectious.

#### **COMPETING INTERESTS DISCLAIMER:**

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

#### **REFERENCES**

1. N. Zhu, D. Zhang, W. Wang, et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019, *N Engl J Med* (2020).
2. M. Chung, A. Bernheim, X. Mei, et al., CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV), *Radiology* (2020) 200230.
3. Y. Pan, H. Guan, Imaging changes in patients with 2019-nCoV, *Eur Radiol.* (2020).
4. V Sethuraman, N.; Jeremiah, S.S.; Ryo, A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA* 2020, 323, 2249–2251. [CrossRef] [PubMed]
5. Nagura-Ikeda, M.; Imai, K.; Tabata, S.; Miyoshi, K.; Murahara, N.; Mizuno, T.; Horiuchi, M.; Kato, K.; Imoto, Y.; Iwata, M.; et al. Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse

- Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test to Diagnose COVID-19. *J. Clin. Microbiol.* 2020, 58, e01438-20. [CrossRef] [PubMed]
6. Mak, G.C.; Cheng, P.K.; Lau, S.S.; Wong, K.K.; Lau, C.S.; Lam, E.T.; Chan, R.C.; Tsang, D.N. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *J. Clin. Virol.* 2020, 129, 104500. [CrossRef] [PubMed]
  7. Lambert-Niclot, S.; Cu\_el, A.; Le Pape, S.; Vauloup-Fellous, C.; Morand-Joubert, L.; Roque-Afonso, A.M.; Le Go\_, J.; Delaugerre, C. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. *J. Clin. Microbiol.* 2020, 58, e00977-20. [CrossRef] [PubMed]
  8. Porte, L.; Legarraga, P.; Vollrath, V.; Aguilera, X.; Munita, J.M.; Araos, R.; Pizarro, G.; Vial, P.; Iruretagoyena, M.; Dittrich, S.; et al. Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples. *Int. J. Infect. Dis.* 2020, 99, 328–333. [CrossRef] [PubMed]
  9. Scohy, A.; Anantharajah, A.; Bodeus, M.; Kabamba-Mukadi, B.; Verroken, A.; Rodriguez-Villalobos, H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. *J. Clin. Virol.* 2020, 129, 104455. [CrossRef] [PubMed]
  10. Mertens, P.; De Vos, N.; Martiny, D.; Jassoy, C.; Mirazimi, A.; Cuypers, L.; Van den Wijngaert, S.; Monteil, V.; Melin, P.; Sto\_els, K.; et al. Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. *Front. Med. (Lausanne)* 2020, 7, 225. [CrossRef] [PubMed]
  11. Blairon, L.; Wilmet, A.; Beukinga, I.; Tre-Hardy, M. Implementation of rapid SARS CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital. *J. Clin. Virol.* 2020, 129, 104472. [CrossRef] [PubMed]
  12. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, Sueki H, Hayakawa M, Mochizuki H, Tsutsui T, Kakizaki Y, Miyashita Y, Yagi S, Kojima S, Omata M. Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients. *Int J Infect Dis.* 2020 Oct;99:397-402. doi: 10.1016/j.ijid.2020.08.029. Epub 2020 Aug 12. PMID: 32800855; PMCID: PMC7422837.
  13. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA.* 2020. In press.
  14. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, Martínez M, Poujois S, Forqué L, Valdivia A, Solano de la Asunción C, Ferrer J, Colomina J, Navarro D. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. *Clin Microbiol Infect.* 2021 Mar;27(3):472.e7-472.e10. doi: 10.1016/j.cmi.2020.11.004. Epub 2020 Nov 13. PMID: 33189872; PMCID: PMC7662075
  15. Xie X, Zhong Z, Zhao W, et al. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. *Radiology.* 2020;200343. In press.
  16. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. *Radiology.* 2020;200432. In Press.
  17. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. *J Clin Microbiol.* 2020 May 26;58(6):e00512-20. doi: 10.1128/JCM.00512-20. PMID: 32245835; PMCID: PMC7269383.

18. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. *J Clin Microbiol.* 2020 May 26;58(6):e00512-20. doi: 10.1128/JCM.00512-20. PMID: 32245835; PMCID: PMC7269383.
19. Acharya S, Shukla S, Acharya N. Gospels of a pandemic-A metaphysical commentary on the current COVID-19 crisis. <https://doi.org/10.7860/JCDR/2020/44627.13774>.
20. Arora D, Sharma M, Acharya S, Shukla S, Acharya N. India in “Flattening the Curve” of COVID-19 Pandemic-Triumphs and Challenges Thereof. *Journal of Evolution of Medical and Dental Sciences.* 2020 Oct 26;9(43):3252-6. <https://doi.org/10.14260/jemds/2020/713>.
21. Bawiskar N, Andhale A, Hulkoti V, Acharya S, Shukla S. Haematological Manifestations of Covid-19 and Emerging Immunohaematological Therapeutic Strategies. *Journal of Evolution of Medical and Dental Sciences.* 2020 Nov 16;9(46):3489-95. <https://doi.org/10.14260/jemds/2020/763>.
22. Burhani TS, Naqvi WM. Telehealth--A Boon in the Time of COVID 19 Outbreak. *Journal of Evolution of Medical and Dental Sciences.* 2020 Jul 20;9(29):2081-5.<https://doi.org/10.14260/jemds/2020/454>.
23. Butola LK, Ambad R, Kute PK, Jha RK, Shinde AD, DMIMS W. The Pandemic of 21st Century-COVID-19. *Journal of Evolution of Medical and Dental Sciences.* 2020 Sep 28;9(39):2913-9. <https://doi.org/10.14260/jemds/2020/637>.
24. Dasari V, Dasari K. Nutraceuticals to Support Immunity: COVID-19 Pandemic-A Wake-up Call. *Journal of Clinical & Diagnostic Research.* 2020 Jul 1;14(7). <https://doi.org/10.7860/JCDR/2020/44898.13843>.
25. Dhok A, Butola LK, Anjankar A, Shinde AD, Kute PK, Jha RK. Role of Vitamins and Minerals in Improving Immunity during Covid-19 Pandemic-A Review. *Journal of Evolution of Medical and Dental Sciences.* 2020 Aug 10;9(32):2296-301.<https://doi.org/10.14260/jemds/2020/497>.
26. Gawai JP, Singh S, Taksande VD, Sebastian T, Kasturkar P, Ankar RS. Critical Review on Impact of COVID 19 and Mental Health.<https://doi.org/10.14260/jemds/2020/470>.